Pathway enrichment analysis of differentially expressed genes identified by RNA sequencing revealed that immune-related gene expression signatures, such as the inflammatory response, TNFA signaling response, interferon gamma response, and interferon alpha response signatures, demonstrated the highest correlation with niraparib treatment in both tumor models regardless of BRCA mutation status (Fig. 1B,F). This evidence concerns the gene IFNG and neoplasm.